STIGALL L. JEREMY 4

What Happened
Jeremy Stigall, Chief Business Officer of ClearPoint Neuro (CLPT), had 30,995 restricted stock units (RSUs) convert into common shares on 2026-03-12. To satisfy tax withholding obligations, 15,151 of those shares were delivered back to the company at $11.53 per share, a withholding value of $174,691. After withholding, Stigall received a net of 15,844 shares. This was a scheduled RSU settlement (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-03-12; Form 4 filed: 2026-03-16.
• Primary actions reported: M = conversion/exercise of derivative (RSU settlement) of 30,995 shares; F = shares surrendered for tax withholding (15,151 shares at $11.53 = $174,691).
• Net shares delivered to insider: 30,995 − 15,151 = 15,844 shares.
• Shares owned after transaction: Not disclosed in the filing.
• Footnotes: (F1) These were RSUs settling into common stock on their scheduled vesting date. (F2) The 15,151 shares were delivered to ClearPoint to satisfy applicable tax withholding.
• Filing timeliness: Form 4 lists the transaction date 3/12 and was filed 3/16; the filing does not indicate a late-reporting flag.

Context
RSU settlements are a common form of compensation for executives and are typically routine. The “M” code here reflects conversion of a derivative (RSU) into shares; the “F” code reflects shares withheld to cover taxes (a non-market sale back to the company). Such withholding transactions do not by themselves signal a decision to sell shares on the open market and should be interpreted as routine tax-related processing of compensation.